Aplastic Anemia Treatment Market Trends

  • Report ID: 3799
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Aplastic Anemia Treatment Market Trends

Growth Drivers

  • Increasing Awareness Campaigns for Aplastic Anemia and Blood Disorders by Public and Private Organizations - Aplastic anemia is a rare, yet potentially life-threatening condition. Through increasing public and private initiatives, more people are becoming aware of the condition and its complications. These initiatives are aimed at educating the general public about the symptoms and causes of aplastic anemia, as well as the available treatments. For instance, NORD - National Organization for Rare Disorders, Inc., the Aplastic Anemia and MDS International Foundation, and CancerIndex sponsor awareness campaigns regarding aplastic anemia. February 2019 saw the launch of the Aplastic Anemia Trust's awareness campaign 'I'm Fantastic Not Aplastic'. As a result, more people will be aware of the condition, leading to increased diagnosis and treatment, thus driving the growth of the aplastic anemia treatment market.
  • Increased Use Of Blood Transfusion Therapy To Treat Diseases - Blood transfusion therapy has been used for decades to treat aplastic anemia, and it is expected to become even more popular in the coming years as medical technology advances and more effective treatments become available. According to WHO, blood transfusions are most frequently performed on patients over 65 in high-income countries, accounting for 76% of all transfusions.
  • Growing Number Of Bone Marrow Diseases - Aplastic Anemia is a serious condition caused by a lack of healthy blood cells in the body. Bone marrow diseases, such as leukemia and myelodysplastic syndromes, can cause the marrow to produce too few healthy blood cells, leading to aplastic anemia. As the number of these diseases increases, the demand for treatments, such as bone marrow transplants, is expected to grow. In the United States, approximately 18,000 people receive bone marrow transplants from related or unrelated matched donors each year for life-threatening illnesses.  
  • Improved Healthcare Infrastructure, And The Growing Popularity of Health Insurance Schemes - With improved healthcare infrastructure, access to specialized treatments for aplastic anemia is becoming easier. People are also more inclined to invest in health insurance plans to cover the costs of treatments. It was observed that over 500 million people in India were covered under health insurance schemes in the fiscal year of 2021, and that number is expected to rise.
  • A Rise In The Prevalence Of Non-Hodgkin Lymphoma Cases - Approximately 80,550 people (44,880 males and 35,670 females) will be diagnosed with non-Hodgkin lymphoma in 2023, according to the American Cancer Society. The number of deaths from this cancer includes both adults and children, with 11,780 men and 8,400 women affected.

Challenges

  • Side effects associated with the medications used to treat the condition - The side effects of the drugs used to treat aplastic anemia can include nausea, vomiting, hair loss, dizziness, irregular heartbeat, and even liver damage. These side effects can make patients reluctant to take the medication, which can limit the effectiveness of the treatment.
  • High cost of treatment
  • Limited availability of donor stem cells

Aplastic Anemia Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

5.1%

Base Year Market Size (2023)

USD 6.72 Billion

Forecast Year Market Size (2036)

USD 12.45 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3799
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of aplastic anemia treatment is assessed at USD 7 Billion.

The aplastic anemia treatment market size was over USD 6.72 Billion in 2023 and is likely to reach USD 12.45 Billion by the end of 2036, witnessing around 5.1% CAGR during the forecast period i.e., between 2024-2036. The increasing number of people being diagnosed with aplastic anemia, improved access to healthcare, and the availability of new and improved treatment options are the major factors expected to drive the market growth.

North America is projected to hold the largest industry share by 2036, due to the availability of advanced treatment options for aplastic anemia, such as bone marrow transplantation, immunosuppressive therapy, and blood transfusions.

F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Allergan, Inc., TauRx Therapeutics Ltd., AbbVie Inc., Novartis AG, Siemens Healthcare GmbH, Pfizer, Inc., Bristol-Myers Squibb Company, Bayers AG
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample